Raltegravir with optimized background therapy for resistant HIV-1 infection

Roy T. Steigbigel, David A. Cooper, Princy N. Kumar, Joseph E. Eron, Mauro Schechter, Martin Markowitz, Mona R. Loutfy, Jeffrey L. Lennox, Jose M. Gatell, Jurgen K. Rockstroh, Christine Katlama, Patrick Yeni, Adriano Lazzarin, Bonaventura Clotet, Jing Zhao, Joshua Chen, Desmond M. Ryan, Rand R. Rhodes, John A. Killar, Lucinda R. GildeKim M. Strohmaier, Anne R. Meibohm, Michael D. Miller, Daria J. Hazuda, Michael L. Nessly, Mark J. DiNubile, Robin D. Isaacs, Bach Yen Nguyen, Hedy Teppler

Research output: Contribution to journalArticle

585 Citations (Scopus)

Abstract

BACKGROUND: Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs. METHODS: We conducted two identical trials in different geographic regions to evaluate the safety and efficacy of raltegravir, as compared with placebo, in combination with optimized background therapy, in patients infected with HIV-1 that has triple-class drug resistance in whom antiretroviral therapy had failed. Patients were randomly assigned to raltegravir or placebo in a 2:1 ratio. RESULTS: In the combined studies, 699 of 703 randomized patients (462 and 237 in the raltegravir and placebo groups, respectively) received the study drug. Seventeen of the 699 patients (2.4%) discontinued the study before week 16. Discontinuation was related to the study treatment in 13 of these 17 patients: 7 of the 462 raltegravir recipients (1.5%) and 6 of the 237 placebo recipients (2.5%). The results of the two studies were consistent. At week 16, counting noncompletion as treatment failure, 355 of 458 raltegravir recipients (77.5%) had HIV-1 RNA levels below 400 copies per milliliter, as compared with 99 of 236 placebo recipients (41.9%, P

Original languageEnglish
Pages (from-to)339-354
Number of pages16
JournalNew England Journal of Medicine
Volume359
Issue number4
DOIs
Publication statusPublished - Jul 24 2008

Fingerprint

Virus Diseases
HIV-1
Placebos
Therapeutics
Integrases
Raltegravir Potassium
Treatment Failure
Drug Resistance
Pharmaceutical Preparations
RNA
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., ... Teppler, H. (2008). Raltegravir with optimized background therapy for resistant HIV-1 infection. New England Journal of Medicine, 359(4), 339-354. https://doi.org/10.1056/NEJMoa0708975

Raltegravir with optimized background therapy for resistant HIV-1 infection. / Steigbigel, Roy T.; Cooper, David A.; Kumar, Princy N.; Eron, Joseph E.; Schechter, Mauro; Markowitz, Martin; Loutfy, Mona R.; Lennox, Jeffrey L.; Gatell, Jose M.; Rockstroh, Jurgen K.; Katlama, Christine; Yeni, Patrick; Lazzarin, Adriano; Clotet, Bonaventura; Zhao, Jing; Chen, Joshua; Ryan, Desmond M.; Rhodes, Rand R.; Killar, John A.; Gilde, Lucinda R.; Strohmaier, Kim M.; Meibohm, Anne R.; Miller, Michael D.; Hazuda, Daria J.; Nessly, Michael L.; DiNubile, Mark J.; Isaacs, Robin D.; Nguyen, Bach Yen; Teppler, Hedy.

In: New England Journal of Medicine, Vol. 359, No. 4, 24.07.2008, p. 339-354.

Research output: Contribution to journalArticle

Steigbigel, RT, Cooper, DA, Kumar, PN, Eron, JE, Schechter, M, Markowitz, M, Loutfy, MR, Lennox, JL, Gatell, JM, Rockstroh, JK, Katlama, C, Yeni, P, Lazzarin, A, Clotet, B, Zhao, J, Chen, J, Ryan, DM, Rhodes, RR, Killar, JA, Gilde, LR, Strohmaier, KM, Meibohm, AR, Miller, MD, Hazuda, DJ, Nessly, ML, DiNubile, MJ, Isaacs, RD, Nguyen, BY & Teppler, H 2008, 'Raltegravir with optimized background therapy for resistant HIV-1 infection', New England Journal of Medicine, vol. 359, no. 4, pp. 339-354. https://doi.org/10.1056/NEJMoa0708975
Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. New England Journal of Medicine. 2008 Jul 24;359(4):339-354. https://doi.org/10.1056/NEJMoa0708975
Steigbigel, Roy T. ; Cooper, David A. ; Kumar, Princy N. ; Eron, Joseph E. ; Schechter, Mauro ; Markowitz, Martin ; Loutfy, Mona R. ; Lennox, Jeffrey L. ; Gatell, Jose M. ; Rockstroh, Jurgen K. ; Katlama, Christine ; Yeni, Patrick ; Lazzarin, Adriano ; Clotet, Bonaventura ; Zhao, Jing ; Chen, Joshua ; Ryan, Desmond M. ; Rhodes, Rand R. ; Killar, John A. ; Gilde, Lucinda R. ; Strohmaier, Kim M. ; Meibohm, Anne R. ; Miller, Michael D. ; Hazuda, Daria J. ; Nessly, Michael L. ; DiNubile, Mark J. ; Isaacs, Robin D. ; Nguyen, Bach Yen ; Teppler, Hedy. / Raltegravir with optimized background therapy for resistant HIV-1 infection. In: New England Journal of Medicine. 2008 ; Vol. 359, No. 4. pp. 339-354.
@article{80932d665fce404b8e9be8fe8f869877,
title = "Raltegravir with optimized background therapy for resistant HIV-1 infection",
abstract = "BACKGROUND: Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs. METHODS: We conducted two identical trials in different geographic regions to evaluate the safety and efficacy of raltegravir, as compared with placebo, in combination with optimized background therapy, in patients infected with HIV-1 that has triple-class drug resistance in whom antiretroviral therapy had failed. Patients were randomly assigned to raltegravir or placebo in a 2:1 ratio. RESULTS: In the combined studies, 699 of 703 randomized patients (462 and 237 in the raltegravir and placebo groups, respectively) received the study drug. Seventeen of the 699 patients (2.4{\%}) discontinued the study before week 16. Discontinuation was related to the study treatment in 13 of these 17 patients: 7 of the 462 raltegravir recipients (1.5{\%}) and 6 of the 237 placebo recipients (2.5{\%}). The results of the two studies were consistent. At week 16, counting noncompletion as treatment failure, 355 of 458 raltegravir recipients (77.5{\%}) had HIV-1 RNA levels below 400 copies per milliliter, as compared with 99 of 236 placebo recipients (41.9{\%}, P",
author = "Steigbigel, {Roy T.} and Cooper, {David A.} and Kumar, {Princy N.} and Eron, {Joseph E.} and Mauro Schechter and Martin Markowitz and Loutfy, {Mona R.} and Lennox, {Jeffrey L.} and Gatell, {Jose M.} and Rockstroh, {Jurgen K.} and Christine Katlama and Patrick Yeni and Adriano Lazzarin and Bonaventura Clotet and Jing Zhao and Joshua Chen and Ryan, {Desmond M.} and Rhodes, {Rand R.} and Killar, {John A.} and Gilde, {Lucinda R.} and Strohmaier, {Kim M.} and Meibohm, {Anne R.} and Miller, {Michael D.} and Hazuda, {Daria J.} and Nessly, {Michael L.} and DiNubile, {Mark J.} and Isaacs, {Robin D.} and Nguyen, {Bach Yen} and Hedy Teppler",
year = "2008",
month = "7",
day = "24",
doi = "10.1056/NEJMoa0708975",
language = "English",
volume = "359",
pages = "339--354",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "4",

}

TY - JOUR

T1 - Raltegravir with optimized background therapy for resistant HIV-1 infection

AU - Steigbigel, Roy T.

AU - Cooper, David A.

AU - Kumar, Princy N.

AU - Eron, Joseph E.

AU - Schechter, Mauro

AU - Markowitz, Martin

AU - Loutfy, Mona R.

AU - Lennox, Jeffrey L.

AU - Gatell, Jose M.

AU - Rockstroh, Jurgen K.

AU - Katlama, Christine

AU - Yeni, Patrick

AU - Lazzarin, Adriano

AU - Clotet, Bonaventura

AU - Zhao, Jing

AU - Chen, Joshua

AU - Ryan, Desmond M.

AU - Rhodes, Rand R.

AU - Killar, John A.

AU - Gilde, Lucinda R.

AU - Strohmaier, Kim M.

AU - Meibohm, Anne R.

AU - Miller, Michael D.

AU - Hazuda, Daria J.

AU - Nessly, Michael L.

AU - DiNubile, Mark J.

AU - Isaacs, Robin D.

AU - Nguyen, Bach Yen

AU - Teppler, Hedy

PY - 2008/7/24

Y1 - 2008/7/24

N2 - BACKGROUND: Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs. METHODS: We conducted two identical trials in different geographic regions to evaluate the safety and efficacy of raltegravir, as compared with placebo, in combination with optimized background therapy, in patients infected with HIV-1 that has triple-class drug resistance in whom antiretroviral therapy had failed. Patients were randomly assigned to raltegravir or placebo in a 2:1 ratio. RESULTS: In the combined studies, 699 of 703 randomized patients (462 and 237 in the raltegravir and placebo groups, respectively) received the study drug. Seventeen of the 699 patients (2.4%) discontinued the study before week 16. Discontinuation was related to the study treatment in 13 of these 17 patients: 7 of the 462 raltegravir recipients (1.5%) and 6 of the 237 placebo recipients (2.5%). The results of the two studies were consistent. At week 16, counting noncompletion as treatment failure, 355 of 458 raltegravir recipients (77.5%) had HIV-1 RNA levels below 400 copies per milliliter, as compared with 99 of 236 placebo recipients (41.9%, P

AB - BACKGROUND: Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs. METHODS: We conducted two identical trials in different geographic regions to evaluate the safety and efficacy of raltegravir, as compared with placebo, in combination with optimized background therapy, in patients infected with HIV-1 that has triple-class drug resistance in whom antiretroviral therapy had failed. Patients were randomly assigned to raltegravir or placebo in a 2:1 ratio. RESULTS: In the combined studies, 699 of 703 randomized patients (462 and 237 in the raltegravir and placebo groups, respectively) received the study drug. Seventeen of the 699 patients (2.4%) discontinued the study before week 16. Discontinuation was related to the study treatment in 13 of these 17 patients: 7 of the 462 raltegravir recipients (1.5%) and 6 of the 237 placebo recipients (2.5%). The results of the two studies were consistent. At week 16, counting noncompletion as treatment failure, 355 of 458 raltegravir recipients (77.5%) had HIV-1 RNA levels below 400 copies per milliliter, as compared with 99 of 236 placebo recipients (41.9%, P

UR - http://www.scopus.com/inward/record.url?scp=47949120697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47949120697&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa0708975

DO - 10.1056/NEJMoa0708975

M3 - Article

C2 - 18650512

AN - SCOPUS:47949120697

VL - 359

SP - 339

EP - 354

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 4

ER -